INTIOTCPharmaceutical PreparationsFiscal year ends December 31
Inhibitor Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.11+0.00 (+0.09%)
Close on Oct 19, 2026
- Market cap
- $19.06M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Who owns Inhibitor Therapeutics's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Francis E. Odonnell Jr | Chief Executive Officer, Director, 10% owner | 85,777,069 | 49.36% | Aug 4, 2026 |
| James A. McNulty | Chief Financial Officer | 46,002,114 | 26.47% | Aug 4, 2026 |
| Michelle Yanez | Director | 1,221,271 | 0.70% | Aug 4, 2026 |
| Samuel P. Sears Jr | Director | 1,229,543 | 0.71% | Aug 4, 2026 |
| Ronald E. Osman | Director, 10% owner | 23,554,985 | 13.55% | Aug 4, 2026 |
| Michael Allen Jerman | Director | 180,411 | 0.10% | Jun 24, 2026 |
| Niraj Vasisht | Director | 200,000 | 0.12% | Jun 1, 2026 |
| E. Osman Irrevocable Trust Ronald III | 10% owner | 47,104,970 | 27.10% | Aug 4, 2026 |
| Robe Capital LLC Black | 10% owner | 20,101,057 | 11.57% | Aug 4, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| James A. McNulty Chief Financial Officer | Jul 1, 2026 | Gift | −3,200,000 | – | – | 19,901,057 |
| Niraj Vasisht Director | May 5, 2026 | Award | +50,000 | – | – | 200,000 |
| Francis E. Odonnell Jr Chief Executive Officer, Director, 10% owner | May 4, 2026 | Award | +50,000 | – | – | 150,000 |
| Michelle Yanez Director | May 4, 2026 | Award | +50,000 | – | – | 1,221,271 |
| E. Osman Irrevocable Trust Ronald III 10% owner | May 4, 2026 | Award | +50,000 | – | – | 23,614,985 |
| Samuel P. Sears Jr Director | May 4, 2026 | Award | +50,000 | – | – | 1,229,543 |
| Michael Allen Jerman Director | May 4, 2026 | Award | +50,000 | – | – | 180,411 |
| Niraj Vasisht Director | Apr 1, 2025 | Award | +50,000 | – | – | – |
| Ronald E. Osman Director, 10% owner | Apr 1, 2025 | Award | +50,000 | – | – | 23,554,985 |
| Michelle Yanez Director | Apr 1, 2025 | Award | +50,000 | – | – | 896,271 |
| Michael Allen Jerman Director | Apr 1, 2025 | Award | +50,000 | – | – | 80,411 |
| Samuel P. Sears Jr Director | Apr 1, 2025 | Award | +50,000 | – | – | 1,279,543 |
| James A. McNulty Chief Financial Officer | Dec 2, 2024 | Gift | +1,000,000 | – | – | 1,946,135 |
| Michelle Yanez Director | Dec 2, 2024 | Gift | +250,000 | – | – | 1,146,271 |
| Michelle Yanez Director | Apr 1, 2024 | Award | +50,000 | – | – | 896,271 |
| E. Osman Irrevocable Trust Ronald III 10% owner | Apr 1, 2024 | Award | +50,000 | – | – | 23,564,985 |
| Samuel P. Sears Jr Director | Apr 1, 2024 | Award | +50,000 | – | – | 1,129,543 |
| Michael Allen Jerman Director | Apr 1, 2024 | Award | +50,000 | – | – | 80,411 |
| E. Osman Irrevocable Trust Ronald III 10% owner | Aug 11, 2023 | Award | +25,000 | – | – | 23,514,985 |
| James A. McNulty See Remarks, 10% owner | May 5, 2023 | Other | +398,135 | – | – | 946,135 |
| James A. McNulty See Remarks, 10% owner | May 5, 2023 | Other | −79,627,069 | – | – | 0 |
| James A. McNulty See Remarks, 10% owner | May 5, 2023 | Other | +20,101,057 | – | – | 26,101,057 |
| Michelle Yanez Director | May 5, 2023 | Other | +796,271 | – | – | 800,673 |
| Pharma International Pty Ltd Mayne 10% owner | Jan 15, 2021 | Other | +2,240,488 | – | – | 204,083,227 |
| Pharma International Pty Ltd Mayne 10% owner | Jul 15, 2020 | Other | +3,189,688 | – | – | 201,842,739 |
| W. Mark Watson Director | Dec 12, 2019 | Buy | +500 | $0.06 | $30 | 1,054,100 |
| Garrison J. Hasara CFO and Treasurer | Dec 2, 2019 | Buy | +13,500 | $0.07 | $945 | 3,972,544 |
| Pharma International Pty Ltd Mayne 10% owner | Jan 15, 2019 | Other | +362,121 | – | – | 198,653,051 |
| E. Brendan Magrab Director | Dec 20, 2018 | Award | +65,000 | $0.08 | $5.20K | 65,000 |
| Robert Daniel Martin Director | Dec 20, 2018 | Award | +60,000 | $0.08 | $4.80K | 116,000 |
| Garrison J. Hasara CFO and Treasurer | Aug 30, 2018 | Sale | −100,000 | $0.27 | $27.00K | 3,959,044 |
| Pharma Ventures Pty Ltd Mayne 10% owner | Jul 15, 2018 | Other | +184,798 | – | – | 198,290,930 |
| Pharma International Pty Ltd Mayne 10% owner | Dec 19, 2017 | Buy | +600,000 | $162660.00 | $97.60B | 198,106,132 |
| Stefan Cross Director | Dec 19, 2017 | Buy | −600,000 | $162660.00 | $97.60B | 0 |
| HedgePath, LLC 10% owner | Jun 30, 2017 | Sale | −2,500,000 | – | – | 79,627,069 |
| Nicholas J. Virca President and CEO | Mar 8, 2017 | Tax withholding | −6,314,219 | $0.34 | $2.15M | 8,727,519 |
| Nicholas J. Virca President and CEO | Mar 8, 2017 | Option exercise | +15,041,738 | – | – | 15,041,738 |
| Stefan Cross Director | Mar 8, 2017 | Option exercise | +300,000 | – | – | 600,000 |
| Stefan Cross Director | Mar 8, 2017 | Option exercise | +300,000 | – | – | 300,000 |
| Richard Dana Ono Director | Mar 8, 2017 | Option exercise | +300,000 | – | – | 300,000 |
| Richard Dana Ono Director | Mar 8, 2017 | Tax withholding | −118,800 | $0.34 | $40.39K | 181,200 |
| Richard Dana Ono Director | Mar 8, 2017 | Tax withholding | −118,800 | $0.34 | $40.39K | 362,400 |
| Richard Dana Ono Director | Mar 8, 2017 | Option exercise | +300,000 | – | – | 481,200 |
| Richard Dana Ono Director | Mar 8, 2017 | Option exercise | +150,000 | – | – | 512,400 |
| Richard Dana Ono Director | Mar 8, 2017 | Tax withholding | −59,400 | $0.34 | $20.20K | 453,000 |
| Garrison J. Hasara CFO and Treasurer | Mar 8, 2017 | Tax withholding | −1,470,478 | $0.34 | $499.96K | 2,029,522 |
| Garrison J. Hasara CFO and Treasurer | Mar 8, 2017 | Option exercise | +3,500,000 | – | – | 5,529,522 |
| Garrison J. Hasara CFO and Treasurer | Mar 8, 2017 | Tax withholding | −1,470,478 | $0.34 | $499.96K | 4,059,044 |
| Garrison J. Hasara CFO and Treasurer | Mar 8, 2017 | Option exercise | +3,500,000 | – | – | 3,500,000 |
| W. Mark Watson Director | Mar 8, 2017 | Tax withholding | −79,200 | $0.34 | $26.93K | 553,600 |
| W. Mark Watson Director | Mar 8, 2017 | Option exercise | +200,000 | – | – | 632,800 |
| W. Mark Watson Director | Mar 8, 2017 | Tax withholding | −158,400 | $0.34 | $53.86K | 432,800 |
| W. Mark Watson Director | Mar 8, 2017 | Option exercise | +400,000 | – | – | 591,200 |
| W. Mark Watson Director | Mar 8, 2017 | Option exercise | +300,000 | – | – | 310,000 |
| W. Mark Watson Director | Mar 8, 2017 | Tax withholding | −118,800 | $0.34 | $40.39K | 191,200 |
| Pharma International Pty Ltd Mayne 10% owner | Nov 15, 2016 | Option exercise | +4,750,569 | – | – | 192,645,799 |
| Pharma International Pty Ltd Mayne 10% owner | Nov 15, 2016 | Option exercise | +4,860,000 | – | – | 197,506,132 |
| Pharma International Pty Ltd Mayne 10% owner | Nov 15, 2016 | Option exercise | +333 | – | – | 192,646,132 |
| Pharma International Pty Ltd Mayne 10% owner | Nov 4, 2016 | Option exercise | +33,333,000 | – | – | 187,895,230 |
| Pharma International Pty Ltd Mayne 10% owner | Nov 4, 2016 | Option exercise | +5,500,000 | – | – | 154,562,230 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.